BioTechUSA Group closed 2025 with revenues in excess of €260 million.

Despite the challenging economic environment, we managed to increase our revenue that year. We entered the elite category of domestic companies with revenues exceeding 100 billion Hungarian forints (HUF), after its revenue rose to 261.9 million Euros, accompanied by an 11% increase in sales. However, the record turnover was accompanied by a slight decline in profitability. EBITDA fell from 27 million Euros to 14.22 million Euros due to persistently high raw material prices.

Geopolitical conflicts, energy price volatility and difficulties in the supply of raw materials continued to strongly influence the dietary supplement and specialty food market in 2025. Nevertheless, our group maintained operational stability and market position in this environment. We are present in 104 countries, operate 51 webshops and have 332 physical stores across Europe. We also work with over 4800 B2B partners worldwide. Growth in 2025 was primarily due to the expansion of our product range and distribution points, as well as a rethink of our pricing and promotional strategy. Combining B2B and B2C sales, we achieved net sales of €261.9 million, while operating profit amounted to €2.84 million and profit after tax to €2.63 million. Our equity increased to €130.73 million, indicating a robust financial position and stable structure. 

Level up with investments and product development. 

In 2025, we continued to invest significant amounts in capital expenditure. Infrastructure developments worth €23.5 million were completed, including automated logistics solutions, energy investments and a shaker logo plant. These developments will form the basis for increased efficiency in the coming period. The highlight of our investments was the handover of the new multilayer protein bar production line, which is currently in the testing phase. Once product development is complete later this year, we will begin production of the new type of protein bars.  

The new production line has the capacity to manufacture 55 million products per year. Having tripled its capacity to 75 million slices per year, the production unit will play a key role in meeting demand for impulse and functional products. Another significant development in 2025 was the launch of a new range of organic vitamin products. Thanks to a multi-year partnership with FC Barcelona, we also introduced Iso Whey Zero protein powder in a Catalan cream flavour. 

20% Hungarian market, 80% exports. 

By 2025, BioTechUSA had further strengthened its presence in Europe and beyond. France, Germany, Slovakia and Spain remained our flagship markets, while the Czech Republic, Romania and the Balkan region also experienced significant growth. The mass retail channel, including hypermarkets, drugstores, and discount chains, closed the year with growth of over 20%. Additionally, pharmacies have become an increasingly important sales channel. 

The recipe for changing consumer habits: the omnichannel strategy. 

Industry trends in 2025 continued to influence consumer habits. Due to persistently high raw material prices, shoppers became more conscious of their spending, with smaller packages and lower-priced products becoming more popular. At the same time, demand for ready-to-drink and ready-to-eat products continued to grow. Once again, the year 2025 proved that our high-quality products and omnichannel strategy is the most effective business solution to these new trends, giving us a wide range of tools both offline and online. We are present on webshops and online marketplaces, as well as in owned, earned and purchased media. We also have a presence on traditional and social media platforms, and offline on the shelves of our own stores and those of our global B2B network partners. These include hypermarkets, sports stores, gyms, pharmacies and gas stations. 

Life goes on, even though the price of raw materials is high.  

‘Last year, the dietary supplement and specialty food market continued to be dominated by a limited supply of protein sources. We made the conscious decision to only partially pass on the increased raw material prices to consumers, so while we achieved record sales, our profitability declined,’ said Bálint Lévai, owner of the BioTechUSA Group, when assessing the year. He added, ‘We are proud that, even in a challenging market, we have maintained the quality and consistency of our products and made investments that will lay the groundwork for growth in the years ahead.’ 

In addition, Balázs Lévai (former sales director) and Bálint Lévai (former CEO) stepped down from operational management with effect from 1 January 2026. From that date, Diána Markovics took over as CEO of our Group. She acted as managing director, responsible for supply areas, until 1 January. Iván Ivanov, who has also been with our company for a long time, has taken over the position of sales director. Together with the new CEO, our owners have established a supervisory board chaired by Bálint Lévai. The aim is to develop more conscious operations and further strengthen the company’s efficiency while preserving the values that have made us successful so far.    

Click here to read the full 2025 annual report from BioTechUSA Group!